Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12916-015-0536-8 http://scihub22266oqcxt.onion/10.1186/s12916-015-0536-8 C4673777!4673777 !26646075     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26646075 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       BMC+Med 2015 ; 13 (ä): 293 Nephropedia Template TP {{tp|p=26646075 |t=2015. Advances in the treatment of newly diagnosed glioblastoma |pdf=|usr=}}{{26646075 }} gab.com Text Advances in the treatment of newly diagnosed glioblastoma JO: BMC Med http://www.kidney.de/pget.php?&tw=1&pmid=26646075 #FOAvip Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted, randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an example of this changing paradigm and these and other immunotherapies have potential as promising new treatment modalities for newly diagnosed GB patients. Twit Text FOAVip Advances in the treatment of newly diagnosed glioblastoma ????BMC Med http://www.kidney.de/pget.php?&tw=1&pmid=26646075 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26646075 #FOAvip English Wikipedia <ref>{{Cite pmid|26646075 }}</ref> Advances in the treatment of newly diagnosed glioblastoma #MMPMID26646075 Theeler BJ ; Gilbert MR BMC Med 2015[Dec]; 13 (ä): 293 PMID26646075 show ga Glioblastoma is a refractory malignancy with limited treatment options at tumor recurrence. Only a small proportion of patients survive 2 years or longer with the current standard of care. Gene expression profiling can segregate newly diagnosed patients into groups with different prognoses, and these biomarkers are being incorporated into a new generation of personalized clinical trials. Using the experience from recently completed large scale, multi-faceted, randomized glioblastoma clinical trials, a new clinical trial paradigm is being established to move promising therapies forward into the newly diagnosed treatment setting. Upcoming trials using the immune check-point inhibitors are an example of this changing paradigm and these and other immunotherapies have potential as promising new treatment modalities for newly diagnosed GB patients. |Brain Neoplasms/pathology/*therapy [MESH] |Glioblastoma/pathology/*therapy [MESH] |Humans [MESH] |Neoplasm Recurrence, Local [MESH]Advances in the treatment of newly diagnosed glioblastoma (epmc).pdf DeepDyve Pubget Overpricing